Skip to content

Corticosteroids for patients with acute respiratory distress syndrome; systematic review and meta-analysis.

Corticosteroids for patients with acute respiratory distress syndrome; systematic review and meta-analysis. - Corticosteroids for patients with acute respiratory distress syndrome; systematic review and meta-analysis.

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000041007
Enrollment
Unknown
Registered
2020-07-05
Start date
2020-07-05
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute respiratory distress syndrome

Interventions

None listed

Sponsors

JA General Hospital.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with ARDS, which was diagnosed by American European Consensus (1994) or Berlin (2012) diagnosis criteria. We will also include patients with acute respiratory failure which is defined as follow: - An acute onset of hypoxemia, with P/F ratio 200 mmHg and less - Bilateral noncardiogenic pulmonary edema - No clinical evidence of increased left atrial hypertension or a pulmonary artery wedge pressure 18 mmHg and less in the presence of a pulmonary artery catheter.

Exclusion criteria

Exclusion criteria: - Cardiac edema - Hypercapnia without hypoxia - Contraindication of steroids - Diseases which steroids is effective - History of steroids use by some months before inclusion - No ventilation - Acute lung injury associated with immaturity and congenital malformations

Design outcomes

Primary

MeasureTime frame
Hospital mortality, the number of ventilator free days, and incidence of infection. If there will be no data of hospital mortality, we will collect 28-60days mortality as short-term mortality. Incidence of infection will collect data of the number of patients with infection during hospital stay. Hospital mortality and incidence of infection will integrate risk ratio. VFDs will integrate mean difference.

Secondary

MeasureTime frame
ICU mortality, ICU length of stay (LOS), hospital LOS, ventilator days and oxygenation. We will collect data of P/F ratio on study day 7 as oxygenation. ICU mortality will integrate risk ratio. ICU LOS, hospital LOS, ventilator days and P/F ratio will integrate mean difference.

Countries

Japan

Contacts

Public ContactShodai Yoshihiro

JA General Hospital Pharmaceutical department

syoshihiro-ja@umin.ac.jp0829-36-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026